What SS-31 actually is, and the one thing it's approved for

Most of the peptides that get talked about in longevity circles are still sitting somewhere in the gap between a lab bench and a clinic. SS-31 is one of the few that has crossed all the way over. In September 2025 the FDA approved it, under the name elamipretide, for a rare inherited disorder called Barth syndrome. As of this spring it is the only mitochondria-targeted peptide with a full approval to its name. That fact is worth sitting with, because it is both more and less than the marketing around SS-31 tends to suggest.

What it does inside the cell

SS-31 is a short peptide, four amino acids long, and it was built to go to one very specific place. Deep inside every mitochondrion, the little compartments that turn food into usable energy, there is a folded inner membrane rich in a fatty molecule called cardiolipin. Cardiolipin is what holds the energy-making machinery in the right shape. When it degrades, the machinery loses efficiency, and cells that lean hardest on energy, like heart and muscle, feel it first.

SS-31 is a cell-penetrating peptide that concentrates at that inner membrane and binds cardiolipin. The idea is that by stabilizing cardiolipin it helps the mitochondrion keep its structure, and with it, its output. That is a clean, specific mechanism, which is part of why the compound has drawn so much research attention. It is not a vague antioxidant story. It has an address.

The one thing it's approved for

Barth syndrome is rare, genetic, and serious. It disrupts cardiolipin directly, which makes it close to a proof-of-concept target for a drug that stabilizes the same molecule. The approval reflects that fit. It says the FDA looked at the evidence in this particular population and found it strong enough to clear the drug for this particular use.

What the approval does not do is stretch to cover the longer list of things SS-31 gets sold for. Access to the approved formulation is restricted to Barth patients. Everything else you read about the peptide, energy, recovery, aging muscle, skin, sits outside that clearance and rests on a different, thinner body of evidence.

Where the wider trials landed

This is the part the supplement listings tend to leave out. SS-31 has been tested well beyond Barth, in heart failure, in age-related conditions, and in a form of inherited muscle disease called primary mitochondrial myopathy. The myopathy program was substantial, and its large Phase 3 trial did not meet its main goals. Results across the other indications have been mixed rather than clearly positive.

None of that makes the mechanism wrong. A drug can do exactly what it does at the membrane and still fail to move the outcomes a trial is built to measure, because biology has more moving parts than any one target. But it does mean the honest summary is narrow. SS-31 works, in the regulatory sense, for one rare disease. For the broader promises, the trials that went looking mostly came back without the result.

How to hold it

There is a pattern worth noticing here, because it repeats across the peptide aisle. A compound earns a genuine, hard-won approval for a specific condition. That approval then gets borrowed as a halo for a much wider set of uses it was never granted for. The word "FDA-approved" travels; the fine print about for what stays behind.

SS-31 is real science with a real mechanism and a real, bounded clearance. That is more than most of what sits beside it can claim. It is also not a permission slip for the rest of the list. The useful question, the same one that works for any peptide, is the plain one: approved for whom, tested in what, and did the trials that aimed wider actually hit.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.